# 5-Amino-1MQ

> 5-Amino-1MQ is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT), studied for a potential role in body composition and metabolic regulation. It is a synthetic quinolinium derivative rather than a peptide, and it gained early attention from preclinical obesity research conducted at Washington University. Interest has since spread into broader metabolic-health and longevity communities, largely through oral capsule formulations. Because NNMT activity is concentrated in adipose and liver tissue, research has focused on fat-cell energy metabolism rather than central nervous system effects. Human clinical trials remain limited, so claims about fat loss or metabolic benefit in people should be treated as unconfirmed.

- URL: https://www.lifeconverted.com/peptides/5-amino-1mq
- Also known as: 5-Amino-1-Methylquinolinium
- Primary category: Metabolic
- Effectiveness rank: #21 in Weight Management; #10 in Metabolic
- Evidence level: Emerging research
- Route: Oral (Most commonly taken as an oral capsule; some vendors offer subcutaneous formulations, but oral use is far more established in practice.)
- Dose range: 50-150 mg
- Dose tiers: low 50 mg; moderate 100 mg; high 150 mg
- Half-life: Approximately 8 hours, based on limited pharmacokinetic data.
- Timing: Morning
- Cycle: 4-12 weeks on, Break before repeating (specific duration not well established) off (Daily oral dosing is typical; standardized cycling protocols have not been established in controlled research.)
- Storage: Store capsules at room temperature, sealed, and away from moisture and light; the oral form does not require refrigeration.

## Mechanism of action

NNMT converts nicotinamide into methylnicotinamide, a reaction that consumes both nicotinamide, an NAD+ precursor, and the methyl donor SAMe. By inhibiting NNMT, 5-Amino-1MQ is theorized to preserve more nicotinamide for NAD+ synthesis and reduce methylnicotinamide buildup in fat and liver tissue. In rodent studies this shift has been associated with increased cellular energy expenditure and reduced fat mass, though translation of these pathways to humans has not been established.

## Reported benefits

- Explored for supporting increased energy expenditure in fat cells
- Studied for potential fat-mass reduction in obesity research models
- Investigated for effects on NAD+ and SAMe balance via NNMT inhibition
- Notable for favorable oral bioavailability compared with most peptide-based options

## Reported side effects

- Mild gastrointestinal discomfort reported anecdotally
- Occasional headache
- Limited long-term human safety data
- Theoretical concern about methyl-donor (SAMe) depletion with prolonged use

## Common protocols

- Daily oral dosing for 4-12 week cycles
- Paired with a caloric-deficit diet and exercise routine
- Combined with other fat-loss-oriented peptides such as AOD-9604

## Stacking notes

Sometimes combined with other fat-loss-focused peptides such as AOD-9604; oral use is generally preferred over injectable forms. No controlled data exist on combined use.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer